Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

Also called NCT01199081

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 154 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01199081
  • EudraCT 2010-019247-19
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Colombia, Czechia, Denmark, France, Germany, Mexico, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01199081. Randomized; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2012-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation
Acronym
ARTEMIS AF LT
Intervention (Drug)
Dronedarone
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01199081
Content hash
6cd8e8df4d3a1ab659a2782d73c77a7c4ff77af6245c5d857e9ad53e59d13c32